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Background
It is now well recognized that somewhere between 10
and 20% of all colon cancers are a result of a highly
penetrant genetic predisposition. The most commonly
identified types of hereditary colorectal cancer are her-
editary non-polyposis colorectal cancer (HNPCC or
Lynch syndrome) which accounts for an estimated 2-5%
of all colorectal cancer patients and familial adenoma-
tous polyposis (FAP) which contributes to about 1% of
them. The occurrence of Lynch syndrome (LS) is asso-
ciated with constitutional mutations in DNA mismatch
repair (MMR) genes. FAP is a result of inactivating
germline mutations in the adenomatous polyposis coli
(APC) gene. An iPLEX test combined with TaqMan
genotyping assays was developed to identify common
recurrent mutations of those genes in the Polish
population.
Materials and methods
349 DNA samples from 95 positive controls, identified
by sequencing and 254 individuals not tested previously
by any method, were analysed. The iPLEX test included
two plexes, comprising 7 mutations of the APC gene
and 29 mutations of three MMR genes: MLH1, MSH2
and MSH6. TaqMan assays were designed for 9 muta-
tions not covered by iPLEX assays, one mutation in
APC gene and 8 mutations in three MMR genes. Results
were verified independently by sequencing to determine
the sensitivity and specificity for iPLEX/TaqMan test in
a blind study.
Results
Our combined method allowed to detect all recurrent
mutations occurred in group of patients, which was sub-
jected to full analysis by DNA sequencing. With the
exception of one false positive in iPLEX test in the
group of positive controls, that could be assigned to
contamination from neighbouring wells rather than a
detection error, given sufficient DNA concentration and
quality, the designed iPLEX/TaqMan test had an accu-
racy of 100% for the designed assays.
Conclusions
Results suggest that the combined iPLEX/TaqMan test
is an outstanding tool for identification of recurrent
mutations among hereditary colorectal cancer patients.
An extension of the test to all known MMR and APC
mutations, and not just the ones currently considered as
recurrent, should be also taken into consideration.
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